Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -319.8%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $147M | $39M | $234124 | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $896314 |
| Enterprise Value | $139M | $31M | $-3565876 | $-21958171 | $-41481180 | $-68744435 | $-13012466 | $-8865630 | $-6056383 | $-6332448 | $-3814490 |
| P/E Ratio → | -0.13 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.82 | 2.61 | 0.04 | 0.04 | 0.02 | 0.03 | 0.11 | 0.10 | 0.08 | 0.08 | 0.06 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -319.8% | -319.8% | -135.8% | -76.1% | -44.3% | -32.8% | -103.7% | -88.5% | -75.7% | -61.1% | -55.2% |
| ROA | -171.9% | -171.9% | -78.9% | -62.3% | -41.0% | -28.1% | -63.8% | -58.9% | -60.8% | -54.7% | -47.8% |
| ROIC | -434.5% | -434.5% | -757.4% | -352.9% | -259.0% | -306.5% | -360.8% | -212.8% | -136.2% | -66.0% | -58.7% |
| ROCE | -187.1% | -187.1% | -124.0% | -70.5% | -46.1% | -43.0% | -82.4% | -93.8% | -91.1% | -53.6% | -54.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.08 | 0.02 | 0.01 | 0.00 | 0.02 | 0.02 | — | — | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.57 | -0.64 | -0.88 | -0.82 | -0.90 | -0.83 | -0.67 | -0.50 | -0.45 | -0.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -89.86 |
Net cash position: cash ($9M) exceeds total debt ($359000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 | 3.78 | 2.06 | 3.75 | 3.88 |
| Quick Ratio | 1.41 | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 | 3.78 | 2.06 | 3.75 | 3.88 |
| Cash Ratio | 1.30 | 1.30 | 0.80 | 3.46 | 8.95 | 19.58 | 5.20 | 3.01 | 1.84 | 3.48 | 3.72 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $12M | $137720 | $79024 | $76278 | $71669 | $26255 | $18098 | $11513 | $8253 | $4368 |
Clinical trial liquidity dependence
Based on reported figures, MBRX trades at a price-to-book ratio of 2.65, which appears to reflect the market's speculative pricing of its clinical pipeline rather than any tangible asset backing, especially when compared to peers like Agios Pharmaceuticals that maintain more established clinical development profiles.
The current valuation multiple is largely untethered from traditional earnings-based metrics, as the company remains pre-revenue and consistently loss-making. Investors should monitor whether this premium over book value is justified by the potential of the Annamycin platform or if it represents an over-optimistic assessment of early-stage clinical data.
As reported in financial statements, MBRX's ROIC has remained deeply negative, reaching -102.4% in 2026Q1, which underscores the company's current inability to generate productive returns on invested capital while it remains in the high-cost, pre-commercial phase of its oncology drug development cycle.
The persistent decay in return metrics is a structural feature of the business model rather than an operational failure, as capital is consumed entirely by R&D rather than deployed into revenue-generating assets. This trend warrants further investigation into whether future clinical milestones can realistically pivot the company toward positive capital efficiency.
According to recent SEC filings, the company's current ratio has fluctuated significantly, dropping to 1.38 in 2026Q1, which suggests a narrowing margin of safety for meeting short-term obligations as the firm continues to burn through its remaining cash reserves to fund ongoing clinical trial activities.
While the current ratio appears superficially adequate, the lack of recurring revenue makes the company highly sensitive to any unexpected clinical delays or supply chain costs. Investors should monitor the cash-to-expense ratio closely, as the current liquidity position may necessitate further dilutive financing to ensure operational continuity.
Based on the provided data, the price-to-book ratio is the most commonly misapplied metric for MBRX, as it obscures the reality that the company's book value is heavily comprised of intangible assets and goodwill rather than liquid capital available for ongoing clinical research and development.
Relying on P/B ratios in this context may lead to a false sense of security regarding the company's asset backing. A more appropriate analytical focus would be the cash-burn-to-market-cap ratio, which better captures the urgency of the company's funding requirements relative to its current valuation.
Includes 30+ ratios · 11 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MBRX stock.
Moleculin Biotech, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Moleculin Biotech, Inc.'s return on equity (ROE) is -319.8%. The historical average is -99.3%.
Based on historical data, Moleculin Biotech, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.